Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial

Thomas A Rasmussen; Martin Tolstrup; Christel R Brinkmann; Rikke Olesen; Christian Erikstrup; Ajantha Solomon; Anni Winckelmann; Sarah Palmer; Charles Dinarello; Maria Buzon; Mathias Lichterfeld; Sharon R Lewin; Lars Ostergaard; Ole S Sogaard

Journal article

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial

Thomas A Rasmussen, Martin Tolstrup, Christel R Brinkmann, Rikke Olesen, Christian Erikstrup, Ajantha Solomon, Anni Winckelmann, Sarah Palmer, Charles Dinarello, Maria Buzon, Mathias Lichterfeld, Sharon R Lewin, Lars Ostergaard, Ole S Sogaard

LANCET HIV | ELSEVIER INC | Published : 2014

DOI: 10.1016/S2352-3018(14)70014-1

University of Melbourne Researchers

Thomas Aagaard Rasmussen Author Doherty Institute

Sharon Lewin Author Doherty Institute

Related Projects (1)

IMPROVED HEALTH OUTCOMES FOR PEOPLE LIVING WITH HIV

Despite the success of antiviral therapy for HIV infection, HIV cannot be cured and treatment is life long. In addition, there are complicat..

Grants

Awarded by Australian National Health and Medical Research Council

Awarded by Division of AIDS, National Institute of Allergy and Infectious Disease, US National Institutes of Health (Delaney AIDS Research Enterprise)

Funding Acknowledgements

We thank Carsten Schade Larsen, Alex Laursen, and Merete Storgaard for clinical guidance during the study and Henrik Stovring for biostatistical support. Amy Shaw provided technical support and Paul W Denton provided input to the drafting of the report. The study was primarily funded by The Danish Council For Strategic Research, but also received contributions from The Danish AIDS Foundation, The Augustinus Foundation, Frode V Nyegaard Foundation, SSAC Foundation, Aarhus University, Aarhus University Hospital, and the American Fund for AIDS Research. Novartis supplied panobinostat for use in the study. SRL's contribution was supported by an Australian National Health and Medical Research Council project grant 1009533, an NHMRC Practitioner Fellowship and the Division of AIDS, National Institute of Allergy and Infectious Disease, US National Institutes of Health (Delaney AIDS Research Enterprise; U19AI096109). We wish to express our sincere gratitude to the study patients for their participation in the study.